Galectin Therapeutics (GALT) Competitors $4.28 +0.03 (+0.71%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.26 -0.02 (-0.49%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. URGN, CRON, IMNM, QURE, PGEN, AKBA, AVXL, NRIX, NAGE, and PHARShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Urogen Pharma (URGN), Cronos Group (CRON), Immunome (IMNM), uniQure (QURE), Precigen (PGEN), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Nurix Therapeutics (NRIX), Niagen Bioscience (NAGE), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Its Competitors Urogen Pharma Cronos Group Immunome uniQure Precigen Akebia Therapeutics Anavex Life Sciences Nurix Therapeutics Niagen Bioscience Pharming Group Urogen Pharma (NASDAQ:URGN) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation. Which has better valuation and earnings, URGN or GALT? Galectin Therapeutics has lower revenue, but higher earnings than Urogen Pharma. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUrogen Pharma$90.40M9.95-$126.87M-$3.32-5.86Galectin TherapeuticsN/AN/A-$47.05M-$0.64-6.69 Does the media prefer URGN or GALT? In the previous week, Urogen Pharma and Urogen Pharma both had 2 articles in the media. Urogen Pharma's average media sentiment score of 1.75 beat Galectin Therapeutics' score of 1.31 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend URGN or GALT? Urogen Pharma currently has a consensus price target of $32.00, indicating a potential upside of 64.52%. Galectin Therapeutics has a consensus price target of $6.00, indicating a potential upside of 40.19%. Given Urogen Pharma's higher probable upside, research analysts clearly believe Urogen Pharma is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is URGN or GALT more profitable? Galectin Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -164.44%. Galectin Therapeutics' return on equity of 0.00% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Urogen Pharma-164.44% -97,487.15% -59.38% Galectin Therapeutics N/A N/A -225.32% Do insiders and institutionals have more ownership in URGN or GALT? 91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, URGN or GALT? Urogen Pharma has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. SummaryUrogen Pharma beats Galectin Therapeutics on 9 of the 14 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$274.18M$2.49B$5.66B$9.84BDividend YieldN/A1.67%3.93%4.04%P/E Ratio-6.6922.8083.2726.61Price / SalesN/A509.21451.26176.28Price / CashN/A177.7737.7059.65Price / Book-2.305.9810.556.59Net Income-$47.05M$32.94M$3.27B$266.12M7 Day Performance4.39%-1.28%0.42%0.17%1 Month Performance18.89%3.54%5.91%3.02%1 Year Performance58.81%-3.68%48.11%19.69% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics2.2393 of 5 stars$4.28+0.7%$6.00+40.2%+56.2%$274.18MN/A-6.699Positive NewsURGNUrogen Pharma4.5518 of 5 stars$19.40-1.6%$31.43+62.0%+38.9%$911.87M$90.40M-5.84200Positive NewsCRONCronos Group1.7776 of 5 stars$2.53+6.8%N/A+18.2%$907.80M$117.61M50.60450Analyst UpgradeIMNMImmunome1.5588 of 5 stars$10.25-0.3%$23.14+125.8%-37.6%$894.82M$9.04M-3.3340News CoverageQUREuniQure2.3625 of 5 stars$15.66-3.2%$37.45+139.2%+162.5%$887.75M$14.34M-3.99500Analyst ForecastPGENPrecigen4.0781 of 5 stars$2.95+0.3%$6.00+103.4%+306.3%$876.04M$3.92M-7.02190AKBAAkebia Therapeutics3.756 of 5 stars$3.11-4.3%$6.75+117.0%+106.6%$861.72M$160.18M-18.29430AVXLAnavex Life Sciences3.8061 of 5 stars$9.59-3.5%$44.00+358.8%+61.5%$854.21MN/A-16.8240Analyst ForecastNRIXNurix Therapeutics2.7312 of 5 stars$10.20-3.6%$28.87+183.0%-62.6%$808.83M$54.55M-3.91300News CoveragePositive NewsAnalyst UpgradeHigh Trading VolumeNAGENiagen Bioscience2.0267 of 5 stars$10.12+1.0%$13.42+32.6%N/A$799.12M$99.60M48.19120PHARPharming Group2.3509 of 5 stars$12.39+6.4%$30.00+142.1%+88.6%$798.20M$297.20M-95.31280Gap Up Related Companies and Tools Related Companies URGN Alternatives CRON Alternatives IMNM Alternatives QURE Alternatives PGEN Alternatives AKBA Alternatives AVXL Alternatives NRIX Alternatives NAGE Alternatives PHAR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts